EHA 2024 Highlights Podcast

In this episode [17.10], Medicom’s correspondent covers 6 presentations from the annual meeting of the European Hematology Association (EHA 2024), held in Madrid, Spain, from 13-16 June 2024.

The topics discussed are:

1.  Excellent phase 3 results for asciminib in CML
   Asciminib was superior to all other tested first-line tyrosine kinase inhibitors in participants with chronic myeloid leukaemia. Also, the treatment with asciminib was associated with fewer adverse events than the standard of care TKIs in the ASC4FIRST trial
2.  Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial
   Isatuximab combined with bortezomib, lenalidomide, and dexamethasone (VRd) yielded better health outcomes than VRd alone for the first-line treatment of transplant-ineligible participants with newly diagnosed multiple myeloma, the phase 3 IMROZ study demonstrated.
3. ENERGIZE: mitapivat meets primary efficay endpoint in thalassaemia
   Mitapivat improved haemoglobin levels and fatigue in participants with non-transfusion-dependent alpha- or beta-thalassaemia in a phase 3 study. These improvements were seen in all subgroups and the agent had a manageable safety profile.
4. ECHO: Can we expect a novel standard of care in newly diagnosed MCL?
   A first-line treatment regimen of acalabrutinib added to bendamustine and rituximab (BR) decreased the risk of disease progression or death compared with a regimen of BR and a placebo in participants with mantle cell lymphoma. The authors also noted a positive trend in overall survival.
5. Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for MF?
   Treatment with pelabresib plus ruxolitinib was associated with improvements in all 4 hallmarks of myelofibrosis, results of the phase 3 MANIFEST-2 trial showed.
6. APOLLO: ATRA plus ATO meets expectations in high-risk APL
   All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) was superior to ATRA-chemotherapy in terms of event-free survival in participants with high-risk acute promyelocytic leukaemia (APL), results of the phase 3 APOLLO trial demonstrated. Further analysis is awaited and will reveal whether ATRA plus ATO should be the new standard of care for the high-risk APL population.

Enjoy listening!

Copyright ©2024 Medicom Medical Publishers

 



Posted on 2 July 20244 July 2024